These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 29397226)

  • 1. Natural immunity against capsular group X N. meningitidis following an outbreak in Togo, 2007.
    Norheim G; Mueller JE; Njanpop-Lafourcade BM; Delrieu I; Findlow H; Borrow R; Xie O; Nagaputra J; Ramasamy R; Dold C; Tamekloe TA; Rollier CS; Watt H; Kere AB; Næss LM; Pollard AJ
    Vaccine; 2018 Feb; 36(10):1297-1303. PubMed ID: 29397226
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical immunogenicity study of trivalent meningococcal AWX-OMV vaccines for the African meningitis belt.
    Tunheim G; Naess LM; Acevedo R; Fjeldheim ÅK; Bolstad K; García L; Cardoso D; Aase A; Zayas C; González H; Rosenqvist E; Norheim G
    Vaccine; 2014 Nov; 32(49):6631-8. PubMed ID: 25305564
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Could the multicomponent meningococcal serogroup B vaccine (4CMenB) control Neisseria meningitidis capsular group X outbreaks in Africa?
    Hong E; Giuliani MM; Deghmane AE; Comanducci M; Brunelli B; Dull P; Pizza M; Taha MK
    Vaccine; 2013 Feb; 31(7):1113-6. PubMed ID: 23261039
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Meningococcal Seroepidemiology 1 Year After the PsA-TT Mass Immunization Campaign in Burkina Faso.
    Tall H; Yaro S; Kpoda HB; Ouangraoua S; Trotter CL; Njanpop Lafourcade BM; Findlow H; Bai X; Martin C; Nwakamma I; Ouedraogo JB; Gessner BD; Borrow R; Mueller JE
    Clin Infect Dis; 2015 Nov; 61 Suppl 5(Suppl 5):S540-6. PubMed ID: 26553686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of a glycoconjugate vaccine to prevent meningitis in Africa caused by meningococcal serogroup X.
    Micoli F; Romano MR; Tontini M; Cappelletti E; Gavini M; Proietti D; Rondini S; Swennen E; Santini L; Filippini S; Balocchi C; Adamo R; Pluschke G; Norheim G; Pollard A; Saul A; Rappuoli R; MacLennan CA; Berti F; Costantino P
    Proc Natl Acad Sci U S A; 2013 Nov; 110(47):19077-82. PubMed ID: 24191022
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Meningococcal carriage and immunity in western Burkina Faso, 2003.
    Yaro S; Traoré Y; Tarnagda Z; Sangaré L; NjanpopLafourcade BM; Drabo A; Findlow H; Borrow R; Nicolas P; Gessner BD; Mueller JE
    Vaccine; 2007 Sep; 25 Suppl 1():A42-6. PubMed ID: 17559988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody persistence in Australian adolescents following meningococcal C conjugate vaccination.
    Perrett KP; Richmond PC; Borrow R; Nolan T; McVernon J
    Pediatr Infect Dis J; 2015 Mar; 34(3):279-85. PubMed ID: 25742078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of size, structure and purity of serogroup X Neisseria meningitidis polysaccharide, and development of an assay for quantification of human antibodies.
    Xie O; Bolgiano B; Gao F; Lockyer K; Swann C; Jones C; Delrieu I; Njanpop-Lafourcade BM; Tamekloe TA; Pollard AJ; Norheim G
    Vaccine; 2012 Aug; 30(40):5812-23. PubMed ID: 22835740
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity of a Meningococcal B Vaccine during a University Outbreak.
    Basta NE; Mahmoud AA; Wolfson J; Ploss A; Heller BL; Hanna S; Johnsen P; Izzo R; Grenfell BT; Findlow J; Bai X; Borrow R
    N Engl J Med; 2016 Jul; 375(3):220-8. PubMed ID: 27468058
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutant Native Outer Membrane Vesicles Combined with a Serogroup A Polysaccharide Conjugate Vaccine for Prevention of Meningococcal Epidemics in Africa.
    Pajon R; Fergus AM; Granoff DM
    PLoS One; 2013; 8(6):e66536. PubMed ID: 23805230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outer membrane vesicles extracted from Neisseria meningitidis serogroup X for prevention of meningococcal disease in Africa.
    Acevedo R; Zayas C; Norheim G; Fernández S; Cedré B; Aranguren Y; Cuello M; Rodriguez Y; González H; Mandiarote A; Pérez M; Hernández M; Hernández-Cedeño M; González D; Brorson SH; Rosenqvist E; Naess L; Tunheim G; Cardoso D; García L
    Pharmacol Res; 2017 Jul; 121():194-201. PubMed ID: 28495657
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Primary and booster mucosal immune responses to meningococcal group A and C conjugate and polysaccharide vaccines administered to university students in the United Kingdom.
    Zhang Q; Lakshman R; Burkinshaw R; Choo S; Everard J; Akhtar S; Finn A
    Infect Immun; 2001 Jul; 69(7):4337-41. PubMed ID: 11401971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population-Level Persistence of Immunity 2 Years After the PsA-TT Mass-Vaccination Campaign in Mali.
    Basta NE; Borrow R; Berthe A; Dembélé AT; Onwuchekwa U; Townsend K; Boukary RM; Mabey L; Findlow H; Bai X; Sow SO
    Clin Infect Dis; 2015 Nov; 61 Suppl 5(Suppl 5):S547-53. PubMed ID: 26553687
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Seroprevalence of bactericidal, specific IgG antibodies and incidence of meningitis due to group A Neisseria meningitidis by age in Burkina Faso 2008.
    Trotter CL; Yaro S; Njanpop-Lafourcade BM; Drabo A; Kroman SS; Idohou RS; Sanou O; Bowen L; Findlow H; Diagbouga S; Gessner BD; Borrow R; Mueller JE
    PLoS One; 2013; 8(2):e55486. PubMed ID: 23457471
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emergence of serogroup X meningococcal disease in Africa: need for a vaccine.
    Xie O; Pollard AJ; Mueller JE; Norheim G
    Vaccine; 2013 Jun; 31(27):2852-61. PubMed ID: 23623866
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical immunogenicity and functional activity studies of an A+W meningococcal outer membrane vesicle (OMV) vaccine and comparisons with existing meningococcal conjugate- and polysaccharide vaccines.
    Tunheim G; Arnemo M; Næss LM; Fjeldheim ÅK; Nome L; Bolstad K; Aase A; Mandiarote A; González H; González D; García L; Cardoso D; Norheim G; Rosenqvist E
    Vaccine; 2013 Dec; 31(51):6097-106. PubMed ID: 24120679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population-based seroprevalence of Neisseria meningitidis serogroup C capsular antibody before the introduction of conjugate vaccine, in Australia.
    Backhouse JL; Gidding HF; MacIntyre CR; McIntyre PB; Gilbert GL
    Vaccine; 2007 Jan; 25(7):1310-5. PubMed ID: 17069937
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Process development and immunogenicity studies on a serogroup 'X' Meningococcal polysaccharide conjugate vaccine.
    Chilukuri SR; Reddy P; Avalaskar N; Mallya A; Pisal S; Dhere RM
    Biologicals; 2014 May; 42(3):160-8. PubMed ID: 24411634
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adolescent meningococcal serogroup A, W and Y immune responses following immunization with quadrivalent meningococcal A, C, W and Y conjugate vaccine: Optimal age for vaccination.
    van Ravenhorst MB; van der Klis FRM; van Rooijen DM; Sanders EAM; Berbers GAM
    Vaccine; 2017 Aug; 35(36):4753-4760. PubMed ID: 28647167
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A broadly-protective vaccine against meningococcal disease in sub-Saharan Africa based on generalized modules for membrane antigens (GMMA).
    Koeberling O; Ispasanie E; Hauser J; Rossi O; Pluschke G; Caugant DA; Saul A; MacLennan CA
    Vaccine; 2014 May; 32(23):2688-95. PubMed ID: 24704334
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.